Nathwani Neil

Montesano Giovanni, Nathwani Neil, Yu Jonathan, Kong Yu Xiang George, Vingrys Algis, Gazzard Gus et al.

Home visual field tests were more variable than clinic tests, but more frequent home testing could detect glaucoma progression earlier than standard clinic visits.

Montesano Giovanni, Crabb David P, Garway-Heath David F, Wright David M, Konstantakopoulou Evgenia, Nathwani Neil et al.

First-line SLT better preserved visual fields over six years than drops in glaucoma/OHT patients. SLT should be preferred as initial treatment.

Konstantakopoulou Evgenia, Gazzard Gus, Garway-Heath David, Adeleke Mariam, Ambler Gareth, Vickerstaff Victoria et al.

Secondary SLT after 3+ years of drops reduced medication for stable glaucoma/OHT patients and lowered IOP for uncontrolled eyes, but didn't eliminate surgery. This supports SLT as a valuable secondary treatment option.

Yang Yangfan, Xu Kezheng, Chen Zidong, Zhang Yuning, Ye Qiaona, Ping Yu-Tzu et al.

This study found most OAG/OHT patients respond well to initial and repeat SLT, with repeat SLT having a longer effect. This supports using repeat SLT regardless of initial response, though some non-responders have distinct features.

Konstantakopoulou Evgenia, Varia Jay, Parmar Janisha, Nathwani Neil, Hau Scott, Low Wing Shing et al.

A training program enabled optometrists to safely deliver SLT for glaucoma, demonstrating that non-medical professionals can expand access to this treatment with proper education.

Founti Panayiota, Narayan Akshay, Raja Aneela, Nathwani Neil, Tur Sergio Bordajandi, Thomas Rachel et al.

This study found many suspected angle closure referrals are inaccurate. Using AS-OCT to triage based on iridotrabecular contact significantly improves efficiency, reducing unnecessary in-person clinic visits.

Gazzard Gus, Konstantakopoulou Evgenia, Garway-Heath David, Adeleke Mariam, Vickerstaff Victoria, Ambler Gareth et al.

The LiGHT trial showed primary SLT offers better long-term glaucoma control than drops, reducing progression and need for incisional and cataract surgeries over six years, making it a safe, effective first-line option.

Yang Yangfan, Zhang Xinyi, Chen Zidong, Wei Yifan, Ye Qiaona, Fan Yanmei et al.

This study found younger age, male gender, and thicker corneas correlated with higher baseline IOP in POAG, and thicker corneas in OHT. Peak IOP often occurred in the morning, aiding glaucoma management.

Konstantakopoulou Evgenia, Jones Lee, Nathwani Neil, Gazzard Gus

Studying optometrist-delivered SLT, research found it acceptable and beneficial for the NHS, but requires standardized training, robust governance, and specific clinical prerequisites for safe implementation.

Yang Yangfan, Jiang Yuzhen, Huang Shitong, Zhang Xinyi, Nathwani Neil, Lin Mingkai et al.

This trial compared SLT versus medication as first-line glaucoma treatment in China. Baseline data showed younger, more myopic patients with worse visual fields than a similar UK study, highlighting population differences in glaucoma presentation.

Wright David M, Konstantakopoulou Evgenia, Montesano Giovanni, Nathwani Neil, Garg Anurag, Garway-Heath David et al.

This study found that initial selective laser trabeculoplasty (SLT) led to less visual field progression in glaucoma/ocular hypertension patients compared to initial medical therapy, suggesting SLT may be a better first-line option.

Garg Anurag, Vickerstaff Victoria, Nathwani Neil, Garway-Heath David, Konstantakopoulou Evgenia, Ambler Gareth et al.

Repeat SLT in medication-naive glaucoma/OHT patients effectively maintains IOP control for at least 18 months, with similar duration of effect to initial treatment, offering a valuable retreatment option.

Garg Anurag, Vickerstaff Victoria, Nathwani Neil, Garway-Heath David, Konstantakopoulou Evgenia, Ambler Gareth et al.

Primary SLT for OAG/OHT showed comparable early IOP lowering to medication, achieving drop-free disease control in ~75% of eyes at 36 months, supporting its effectiveness and safety.

Gazzard Gus, Konstantakopoulou Evgenia, Garway-Heath David, Garg Anurag, Vickerstaff Victoria, Hunter Rachael et al.

This study found SLT is as effective as eye drops for first-line glaucoma/ocular hypertension treatment, with 74% needing no drops at 3 years and being more cost-effective, supporting its routine use.

Konstantakopoulou Evgenia, Gazzard Gus, Vickerstaff Victoria, Jiang Yuzhen, Nathwani Neil, Hunter Rachael et al.

The LiGHT trial compared initial SLT versus medication for glaucoma/OHT, finding baseline patient characteristics were consistent with other studies, paving the way for crucial real-world treatment efficacy and cost-effectiveness comparisons.

Lawlor Mitchell, Quartilho Ana, Bunce Catey, Nathwani Neil, Dowse Emily, Kamal Debbie et al.

Normal tension glaucoma patients show less relative afferent pupillary defect for a given visual field loss than high-pressure glaucoma patients, suggesting differing damage mechanisms and potentially mitochondrial involvement in NTG.

Bergin Ciara, Redmond Tony, Nathwani Neil, Verdon-Roe Gay Mary, Crabb David P, Anderson Roger S et al.

This study found that increased intraocular straylight significantly affected standard, FDT, and FDF perimetry, but the Moorfields Motion Displacement Test (MDT) was largely unaffected, indicating its resilience in conditions like cataract.